

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/283728452>

Oxidative stress and Parkinson's disease: New hopes in treatment with herbal antioxidants

Article in *Current pharmaceutical design* · November 2015

CITATIONS

43

READS

1,053

4 authors, including:



Mahmoud Bahmani

219 PUBLICATIONS **2,021** CITATIONS

[SEE PROFILE](#)



Hedayatollah Shirzad

Shahrekord University of Medical Sciences

106 PUBLICATIONS **1,357** CITATIONS

[SEE PROFILE](#)



Mahmoud Rafeian-kopaei

Shahrekord University of Medical Sciences

337 PUBLICATIONS **5,110** CITATIONS

[SEE PROFILE](#)

Some of the authors of this publication are also working on these related projects:



Genetic mapping of deafness in Iran [View project](#)



expression of anti-oxidative stress genes in ulcerative colitis [View project](#)


Oxidative Stress and Parkinson's Disease: New Hopes in Treatment with Herbal Antioxidants

Amir Sarrafchi¹, Mahmoud Bahmani², Hedayatollah Shirzad¹ and Mahmoud Rafieian-Kopaei^{1*}

¹Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran; ²Food and Beverages Safety Research Center, Urmia University of Medical Sciences, Urmia, Iran

Abstract: Parkinson's disease (PD) is a neurodegenerative disorder due to dopamine deficit in substantia nigra. PD is mainly a sporadic disease with unestablished etiology. However, exposure to environmental toxins, head trauma, inflammation, and free radicals are potential reasons. Recently, the role of oxidative stress in neurological abnormalities, including PD, has been particularly addressed. Antioxidant remedies, particularly herbal antioxidants, have revealed new perspectives of research and therapy as possible preventive and therapeutic approaches for PD. In this paper, we reviewed the recently published papers on the effects of herbal medicines on PD alongside the pathogenesis of PD with regard to oxidative stress.

Keywords: Antioxidant, Degenerative disorder, Herbal medicines, Medicinal plants, Oxidative stress, Parkinson's disease.



INTRODUCTION

Parkinson's disease (PD) is the second most common neurodegenerative disorder which is caused by reduction in dopamine level and loss of projecting dopaminergic neurons in striatum and substantia nigra [1]. Dopaminergic impairment in PD leads to alterations in basal glutamatergic synaptic transmission of striatum and plasticity in the medium spiny neurons [1]. PD affects 2% of the population older than 65 years, with 7-10 million individuals affected worldwide [2]. Its symptoms include resting tremor, rigidity of muscles, bradykinesia, and postural and gait impairments [3].

The most cases of Parkinson's disease are sporadic, with undetermined etiology. However, exposure to environmental toxins, head trauma, inflammation, and free radicals are potential reasons [4, 5]. Remarkable neuroinflammation which is exacerbated by free radicals has been reported in the substantia nigra in the patients with PD [6]. The neurotoxins and cytokines released from the reactive inflammatory cells cause distraction of the projecting dopaminergic neurons in striatum and substantia nigra [6]. Neuroinflammation inhibition in the striatum and substantia nigra has been shown to significantly ameliorate the behavioral deficiency in PD [7].

Recently, special attention has been paid to the role of oxidative stress in neurological abnormalities, including PD. In fact, excessive production of reactive oxidative species (ROS) has been considered as the cause of neuronal death [8, 9].

There is no cure for PD yet, and treatment is mainly symptomatic. The therapies based on a dopamine replacement consist of the use of dopamine precursors; however, substantial adverse effects may appear in long-term usage. Novel pharmacotherapy and cell replacement, before being routinely used in humans, need extensive evaluation [10].

The evidence that mitochondria and ROS as the main neurodegeneration players have caused antioxidant remedies opens new perspectives of research and therapy as possible preventive and therapeutic approaches for PD [11].

In fact, PD usually starts long before its manifestations appear. Therefore, the diets and medicinal plants with low side effects to prevent them as well as knowledge of the first appearing biomarkers and diagnostic methods to disguise the progressing disease at early stages are important. Medicinal plants with antioxidant activities, which are effective on PD have been recently reviewed [12]. However, this review article only covers the Indian plants. In this paper, we reviewed the recently published papers on the effects of herbal medicines on PD alongside the pathogenesis of PD with regard to oxidative stress.

PATHOGENESIS OF PD

About 50 years ago the dopaminergic defect was suggested as the main neurochemical cause of PD; however, the exact causes of this disease are not clear. About 10% of the patients with PD are estimated to have mutations in selected genes. However, it has further complicated the general picture about the underlying factors of PD [13].

In PD, there is a loss of dopaminergic neurons in substantia nigra with projecting nerve fibers residing in the striatum. These neurons play a crucial role in control of voluntary movements, and their degeneration usually leads to debilitating symptoms including resting tremor, muscular rigidity, postural imbalance, and bradykinesia. Aging is an important variable associated with the onset of PD. So that, deficits in the normal cellular function that usually occur with aging increase the vulnerability of dopaminergic neurons [14].

There is no single causative factor to identify sporadic PD. In fact, a multi-factorial nature contributes to the process of nigral cell death, of which mitochondrial dysfunction and elevated levels in formation of ROS are the most important mechanisms [15]. Another factor which may contribute to the neuronal loss underlying PD is neuro-inflammation which in turn increases the ROS and exacerbates PD. The inflammatory response associated with the cell loss in the dopaminergic nigrostriatal tract and the role of immune mechanisms, which are associated with oxidative stress, are being increasingly addressed as important factors in the pathogenesis of PD [13].

*Address correspondence to this author at the Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran; Tel/Fax: +98 383 3330709; E-mail: rafieian@yahoo.com

The Role of Free Radicals in PD

Although familial forms of PD have been described, ROS is likely the main underlying mechanism in both genetic and idiopathic cases of PD, leading to cellular dysfunction of dopaminergic neurons. In this regard, the substantia nigra of PD patients contains higher levels of oxidized lipids, DNA and proteins as well as lower levels of glutathione (GSH) [16].

Oxidative stress is potential when there is an imbalance between ROS production and cellular antioxidant activity [17, 18]. The major sources of ROS which cause oxidative stress and deficit in nigral dopaminergic neurons seem to be mitochondrial dysfunction, neuroinflammation and dopamine metabolism [8].

Mitochondria are the main cellular source of free radicals and have a crucial role in oxidative phosphorylation and electron transport [19]. Mitochondria are also involved in calcium homeostasis and regulation and instigation of cell-death pathways. Hence, there is a complex interaction between mitochondria function and other parts of cellular machinery which affects cell survival. Notably, mitochondrial dysfunction is not detected in all patients with PD. However, this factor may have a critical contribution in the future treatment [20].

Opening of the mitochondrial permeability transition pore is a process which usually occurs under oxidative stress, leading to collapse of the mitochondrial membrane potential. Oxidative stress and mitochondrial dysfunction cause activation of apoptotic pathways in response to pro-apoptotic molecules. Mitochondrial dysfunction causes impairment of energy metabolism which in turn renders the cells vulnerable to 'excitotoxicity'. This excitotoxicity increases ROS generation which in turn increases cellular injury [8]. Mitochondrial dysfunction through increasing oxidative stress induces damage to lipids, DNA and proteins and decreases the levels of intrinsic antioxidants [16].

Higher plasma level of 8-hydroxydeoxyguanosine has been reported in patients with PD than in controls. More importantly, increased serum uric acid level, which is a potent antioxidant, is associated with a lower risk of PD [21].

THE ROLE OF DOPAMINE IN INDUCTION OF OXIDATIVE STRESS

Although the symptoms of PD can be controlled by drugs such as levodopa, the benefits of these drugs usually diminish or become less consistent over time. Levodopa is the most effective medication for PD. It passes into the brain and is converted to dopamine. Levodopa is usually used in combination with carbidopa or benserazide which reduce the metabolism of levodopa outside the brain [22].

As already mentioned, the oxidative stress is one of the main causes of cellular dysfunction and PD patients have high levels of oxidized lipids, proteins and DNA in their substantia nigra, as well as low level of reduced GSH. Due to the presence of ROS-generating enzymes like monoamine oxidase and tyrosine hydroxylase, the dopaminergic neurons are prone to oxidative stress. The major sources of this oxidative stress are dopamine quinone which is produced during dopamine metabolism. In this regard, excess cytosolic dopamine is readily oxidized, producing dopamine quinone. Dopamine quinone is able to modify some of proteins such as DJ-1, UCH-L1 and α -synuclein whose dysfunctions have been shown to be associated with dopamine pathophysiology. α -Synuclein permeabilizes the vesicle membrane, causing leakage of dopamine into the cytosol, which induces dopamine quinone generation [16]. Moreover, dopamine quinone-modified α -synuclein is able to inhibit normal degradation of other proteins. Furthermore, dopamine quinone species are able to modify the cellular molecules such as protein cysteinyl residues and GSH with normal functions being crucial for cell survival. Dopamine quinone induces the conversion of α -synuclein to cytotoxic form, as well [23].

DJ-1 and UCH-L1 have a cysteine residue which is crucial for their activities. The oxidative modification of their cysteine has been reported in PD patients [24]. Dopamine quinone also can lead to dysfunction of mitochondria and inactivation of tyrosine hydroxylase and dopamine transporter [16]. Furthermore, the proteins that assist in protein folding in endoplasmic reticulum, including protein disulfide isomerase-5 and ER-60/GRP58/ERp57, are also modified by dopamine quinone [22]. Dopamine quinone also induces proteasomal inhibition leading to apoptosis of the cells [25]. Moreover, dopamine quinone is able to cyclize and become the highly reactive aminochrome. In this form the redox-cycling can lead to depletion of cellular nicotinamide adenine dinucleotide phosphate (NADPH) and generation of superoxide, and ultimately it may polymerize to form neuromelanin which exacerbates the neurodegenerative process by triggering neuro-inflammation [26]. Neuromelanin is one of the final products of dopamine oxidation and is accumulated in the nigral region. Furthermore, during dopamine metabolism by monoamine oxidase, hydrogen peroxide is also generated which is converted to the highly reactive hydroxyl radical in the presence of transition metal ions, inducing oxidative stress [16].

Dopamine has been shown to cause selective toxicity to dopaminergic terminals proportional to the levels of dopamine oxidation and quinone-modified proteins [27]. Cysteinyl-catechol derivatives also are found in higher than normal levels in postmortem nigral tissues of patients with PD, suggesting cytotoxic nature of dopamine oxidation [16].

The toxic nature of dopamine oxidation suggests that plant antioxidants may have preventive and/or curative effect on PD.

ANTIOXIDANTS AS A TREATMENT STRATEGY OF PD

Coenzyme Q10 (CoQ10) is an antioxidant which acts as a potent electron transporter for mitochondrial complexes I and II. CoQ10 levels are low in mitochondria of patients with PD. The ratio of oxidized CoQ10 to reduced one is higher in PD patients than in controls, representing higher oxidative stress in PD patients [28]. In a randomized placebo-controlled trial, high-dose of CoQ10 (1200 mg/day) in conjunction with α -tocopherol, was capable of slowing the progression of disease [29]. Large clinical trials are now being planned to investigate the potential effects of CoQ10 and other antioxidants as disease-modifying agents. Resveratrol which is a polyphenolic compound in grape skin with antioxidant activity induces expression of genes involved in oxidative phosphorylation and mitochondrial biogenesis. It is able to protect 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced dopaminergic neuron injury in mice [30].

The strategies to counteract ROS and oxidative stress have been shown to be effective in most ROS-induced diseases such as cancer [31, 32], diabetes mellitus [33, 34], atherosclerosis [35, 36] and infectious diseases [37, 38], rather than PD and some other neurological diseases [39, 40]. Although there are some encouraging data suggesting that the compounds affecting mitochondrial function and antioxidant level may slow down PD progression, the data from human studies are not enough to arrive at a definite conclusion. In this regard, the results obtained from medicinal plants with antioxidant activity are encouraging [41, 42].

MEDICINAL PLANTS AND THEIR BYPRODUCTS IN PD

Medicinal plants have recently attracted considerable attention due to prevention and treatment of various diseases including PD [42-44]. A lot of medicinal plants and their formulations have been investigated with regard to PD and can be an alternative for drug discovery. The plants and their components presented here are the most promising candidates for new formulations.

1. *Acanthopanax senticosus*

Acanthopanax senticosus is from the Araliaceae family. The ethanol extract of this plant has been shown to exert protective effect on dopaminergic neurons in rodent models of PD. It also increases dopamine and noradrenaline levels in PD rat model [45]. Sesamin is one of *A. senticosus* components which modulates catalase (CAT), superoxide dismutase (SOD), tyrosine hydroxylase (TH), inducible nitric oxide synthase (iNOS) and interleukin-6 expression in dopaminergic cells against oxidative stress induced by 1-methyl-4-phenylpyridine (MPP) [46, 47].

2. *Alpinia oxyphylla*

Alpinia oxyphylla Miq. is from Zingiberaceae family. Its dried, ripe seeds and ethanol extract protect against 6-OHDA-induced damage to dopaminergic neurons and PC12 cells in zebrafish [48]. Protocatechuic acid derived from *A. oxyphylla* is effective on PD in animal models. It also inhibits MPTP-induced neurotoxicity in mice and reduces sodium nitroprusside- or hydrogen peroxide-induced cell death in PC12 cells [49].

3. *Astragalus membranaceus*

Astragalus membranaceus var. *mongholicus* is from Leguminosae family. Astragaloside IV prepared from this plant prevents MPP+-induced SH-SY5Y cell death by inhibition of ROS production. Astragaloside IV prevents 6-OHDA induced death of dopaminergic neurons in a dose-dependent manner [50]. Astragalus polysaccharides derived from this plant can prevent the toxicity of bendopa caused by free radicals produced by self-oxidation which could promote the development of PD [51].

4. *Camellia sinensis*

Green tea produced from the leaves of *Camellia sinensis* (Theaceae family) can reduce the risk of PD [52]. It also attenuates 6-OHDA-induced cell death in SH-SY5Y cells. The green tea catechins have also preventive effects on the SH-SY5Y cells and PD in rat model, via inhibition of ROS-nitrogen monoxide (NO) pathway [53]. The main components of catechins include (-)epicatechin gallate, (-)epigallocatechin-3-gallate, (-)epigallocatechin, and (-)epicatechin, all of which catechins have protective activity on PC12 cells with the best effect by (-)epicatechin gallate. (-)Epigallocatechin-3-gallate has been shown, in dopaminergic SH-SY5Y cells, to reduce dichlorodiphenyl-trichloroethane-induced cell death and regulate dopamine transporter through protein kinase C in MPP+ induced PC12 cells [54]. (-)Epigallocatechin-3-gallate is also able to inhibit cell death and iNOS expression in the MPTP-induced mice model of PD [55, 56]. Notably, this plant in various studies has shown high antioxidant activity [57, 58].

5. *Cassia obtusifolia*, *Cassiae semen* or *Cassia tora*

Ethanol extract of *Cassia obtusifolia*, *Cassiae semen* or *Cassia tora* L. (Leguminosae family) protect dopamine neuronal degradation induced by MPTP and are also effective against neurotoxicities induced by 6-OHDA in PC12 cells [59]. Peroxynitrite (ONOO)-toxicity is involved in neurodegenerative and inflammatory diseases such as PD. Alaternin isolated from this plant has potent ONOO-scavenging activity and anti-inflammatory property, which makes it a suitable candidate for PD [60].

6. *Chrysanthemum morifolium* and *Chrysanthemum indicum*

Chrysanthemum morifolium Ramat (Asteraceae family) can prevent the cytotoxicity and enhance cell viability in MPP+-induced SH-SY5Y cells [61]. *C. indicum* L. is effective against MPP+ induced damage in SH-SY5Y cells [62]. The positive effects of these plants are not clear in *in vivo* studies.

7. *Cistanche deserticola*, *Cistanche tubulosa* and *Cistanche salsa*

Cistanche deserticola, *Cistanche tubulosa*, and *Cistanche salsa* (Orobanchaceae) have protective activity on dopaminergic neurons of MPTP-induced PD in mice [63]. Echinacoside, isolated and purified from *C. salsa* protects the striatal monoamine neurotransmitters levels from diminution in 6-OHDA-induced lesion in rats. It also has neuroprotective, neurorescue and neurotrophic effects on MPTP-induced mice model of PD [64]. Acteoside, isolated from these plants, has neuroprotective effects against MPTP-induced mice model of PD and rotenone-induced damage of SH-SY5Y cells [65].

8. *Cuscuta australis* and *Cuscuta chinensis*

Cuscuta australis and *Cuscuta chinensis* (Convolvulaceae) are able to protect cells from apoptosis induced by MPP+ and salvianic acid in PC12 cells [66].

9. Ergot alkaloids

The ergot alkaloids have antiserotonin, dopaminomimetic, and antiadrenergic activities and have a broad spectrum of pharmacological effects. Ergot alkaloids have sedative effect on the central nervous system and therapeutic effects against migraine, postpartum haemorrhages, and mastopathy [67].

Most of the ergot alkaloids effects seem to result from their actions as partial agonists or antagonists at serotonergic, dopaminergic, adrenergic, and tryptaminergic receptors. These effects depend on the species, agent, tissue, dosage, and physiological conditions. But, some of their actions are not compatible with this view. For example, while the agonistic effects of ergot are apparent at lower concentrations, the action of methysergide on cerebral blood vessels is opposite. In this regard, few rules on structure-activity relationships have emerged for ergot alkaloids. Small amide derivatives of lysergic acid are relatively selective and potent antagonists of 5-HT; however, the amino acid alkaloids mostly are less selective and reveal similar affinities as blocking agents at tryptaminergic and α -adrenergic receptors [68].

Most studies of ergot derivatives and PD have evaluated their effects on dopamine receptors. Ergoline ring has a structural similarity to the endogenous monoamines which can explain the action of these compounds on serotonergic, dopaminergic, and adrenergic receptors. Pergolide, bromocriptine, and lisuride are presently available as oral ergot dopamine agonists. Bromocriptine, which has weak D₁ receptor antagonistic property and D₂ agonist effect, was the first ergoline recommended for PD. Both pergolide and bromocriptine are effective on relieving the symptoms of PD and reducing the on-off fluctuations of the disease. Pergolide which is the synthetic ergoline derivative has a mild D₁ receptor agonistic effect and a long acting agonistic action at D₂ dopamine receptors [67]. Two drugs possess similar efficacy and adverse effects. The efficacy of long acting bromocriptine is the same as the standard bromocriptine; however, the patients need fewer daily doses. Lisuride is a mild D₁ receptor agonist and a potent postsynaptic striatal D₂ receptor agonist. Its anti PD effect is equivalent to that of pergolide and bromocriptine [68].

Lisuride is a water-soluble drug and hence it can be used intravenously. For control of motor fluctuations of PD, lisuride is very effective when administered by continuous infusion. Its parenteral use might be complicated by incidence of psychiatric side effects, probably due to its serotonergic activities [67, 69].

10. *Fraxinus rhynchophylla*, *F. chinensis*, *F. szaboana*, *F. sielboldiana*

Fraxetin derived from these plants has antioxidant activity, reduces stress proteins, and is able to prevent the apoptotic death of

dopaminergic cells mediated by oxidative stress caused by rotenone in SH-SY5Y cells [70]. Liriodendrin and esculin, extracted from *F. sielboldiana* have anti-apoptotic effects on dopamine or MPP+-induced cytotoxicity in SH-SY5Y cells [71, 72].

11. *Gastrodia elata*

The ethanol extract of *G. elata* (Orchidaceae) possesses protective activity against MPP+-induced cytotoxicity on dopaminergic SH-SY5Y cells [73]. Vanillyl alcohol, a potent component of this plant, is able to protect dopaminergic MN9D cells through modulating the apoptotic process and antioxidant activity, against MPP+-induced apoptosis. Therefore, it is a potential candidate for management of neurodegenerative complications such as PD [74].

12. Ginseng

Ginseng is a deciduous perennial shrub of any one of the 11 species of slow-growing plants belonging to the genus *Panax* of the family Araliaceae. In fact, ginseng is a variety plants, mainly Korean or Asian ginseng (*Panax ginseng*), American ginseng (*Panax quinquefolius*), and Siberian ginseng (*Eleutherococcus senticosus*). *Panax ginseng* is an important plant which has long been used in traditional Chinese medicine for treatment of weakness and fatigue [75].

Ginseng grows in eastern Asia and North America, typically in cooler climates. Fleshy root of ginseng requires about 5 years of cultivation to reach maturity. Traditionally, the wild root was consumed to strengthen, rejuvenate, and vitalize the entire body. Korean ginseng is more suitable for older people and men. Ginseng is believed to be an anti-aging herb and is a favorable herb due to low toxic effects on the body. Korean ginseng is thought to contain adaptogens which can return the body's system back to normal level. In this regard, ginseng is used to balance the metabolism, increase energy levels, lower cholesterol, stimulate the immune system, reduce nervousness, and alleviate fatigue. Korean ginseng can stimulate the regeneration of damaged cells, promote detoxification, and enhance the feeling of wellbeing through increasing oxygenation to cells [75, 76].

Ginseng root has anti-aging, anti-cancer, and cardiovascular protective properties which are potentially due to its high level of antioxidant activity. There are 28 kinds of ginsenosides in American ginseng which can improve impairments in movement and loss of neurons in the brain. Ginseng has been shown to be effective in Huntington's disease or other neuropsychological disorders [75, 77].

13. *Gynostemma pentaphyllum*

The whole plant ethanol extracts of *Gynostemma pentaphyllum* (Cucurbitaceae) have protective effects on 6-OHDA-induced rat model of PD [58]. Gypenosides extracted from *G. pentaphyllum* have neuroprotective activity against dopaminergic neurons in the substantia nigra of mice model of PD against MPP+-induced oxidative injury [78, 79].

14. *Hypericum perforatum*

The methanol extract of *Hypericum perforatum* L. (Guttiferae) has protective effects against MPTP-induced PD in mice [80]. The extract of *H. perforatum* decreases oxidative stress and enhances gene expression of antioxidant enzymes on rotenone-exposed rats [81]. The whole extract and a flavonoid-rich extract from *H. perforatum* have also neuroprotective effects against trauma induced by H₂O₂ in PC12 cells. Hyperoside isolated from *H. perforatum* has been shown to protect the PC12 cells from the cytotoxicity induced by tert-butyl hydroperoxide and H₂O₂ [82].

15. *Ligusticum chuanxiong*

Ligusticum chuanxiong Hort. (Umbelliferae) and tetramethylpyrazine, one of its active components, are able to decrease the

oxidative damage in PD induced by levodopa and improve the dopamine metabolic ratio in the rat striatum [83]. Tetramethylpyrazine is also able to protect dopaminergic neurons against MPTP-induced neurotoxicity in mice model of PD [84].

16. *Mucuna pruriens*

Mucuna pruriens is from the Fabaceae family and Faboidaceae subfamily. *M. pruriens* is an annual twinning plant in bushes and hedges. It is one of the popular medicinal plants indigenous to tropical countries like India [85].

It is useful in relieving inflammation, delirium, neuropathy, cephalagia, and general debility, nephropathy, dysmenorrhoea, amenorrhoea, ulcers, constipation, elephantiasis, consumption, helminthiasis, fever, and dropsy. The trichomes of pods contain serotonin and mucunain. The trichomes are used as anthelmintic. Seeds contain glutathione, gallic acid, levodopa (4-3, 4-dihydroxy phenylalanine), lecithin, prurenine, prurenidine, glycosides, nicotine, minerals, and dark brown viscous oil [85].

In a double-blinded clinical and pharmacological study the plant was assessed for levodopa pharmacokinetics and clinical effects at two different doses in comparison with standard levodopa/carbidopa. Thirty g *M. pruriens* preparation caused shorter latencies as compared to peak levodopa plasma concentration and considerably faster onset of effect. Mean time was 37 min (21%) longer with 30 g *M. pruriens* than with levodopa/carbidopa; peak levodopa plasma concentration was 110% higher and the area under the curve was 165.3% larger. There was no significant difference in tolerability or dyskinesia [86]. The longer action and rapid onset without increase in adverse effect suggest that *M. pruriens* seed powder with natural source of levodopa possibly has advantages over conventional levodopa preparations in treatment of PD. In this regard, evaluation of long term efficacy and tolerability in large controlled trials is required.

In an animal model of PD, *M. pruriens* (drug HP-200) was found to be better in comparison to synthetic levodopa. In this study administration of *M. pruriens* at doses of 2.5, 5.0 or 10.0 g/kg/day for 52 weeks significantly increased the dopamine content of the cortex. However, it had no significant effect on dopamine, levodopa, norepinephrine, serotonin or their metabolites in the nigrostriata. The ability of this plant to improve PD symptoms and failure to exert significant effect on dopamine metabolism in the striatonigral tract may suggest a levodopa enhancing effect or that its effect might be due to components other than levodopa [87].

17. *Paeonia lactiflora* Pall

In traditional Chinese medicine the dried root of *Paeonia lactiflora* (Ranunculaceae) and its principal bioactive component, Paeoniflorin, are widely used for the treatment of neurodegenerative disorders like PD. Paeoniflorin was also able to alleviate the neurological impairment induced by unilateral striatal 6-OHDA lesion in rat model and acidic damage through autophagic pathway [88, 89]. It also attenuates dopaminergic neurodegeneration and neuroinflammation in the mice model of PD by activation of adenosine receptors [90, 91]. Therefore, it could be a good candidate for the treatment of neurodegenerative diseases like PD.

18. *Polygala tenuifolia* Willd and *Polygala sibirica* L.

The water extract from the root of *Polygala tenuifolia* and *Polygala sibirica* L. (Polygalaceae) are able to prevent toxin-induced neuronal death in the PC12 cells caused by MPP+. Tenuigenin is an active component from *P. tenuifolia* and is able to protect the dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharides (LPS) or induced by 6-OHDA in SH-SY5Y cells [92, 93].

19. *Polygonum cuspidatum* Sieb

The dried root and rhizoma of *Polygonum cuspidatum* (Polygonaceae) and resveratrol, prepared from this plant are able to increase degradation of α -synucleins in expressing PC12 cell lines, to prevent neurotoxicity induced by human prion protein and to protect SH-SY5Y cells against rotenone-induced apoptosis. They are also able to modulate the markers of apoptotic death in dopaminergic neurons against MPP+-induced oxidative stress. Resveratrol has protective effects on MPTP-induced neuron loss mediated by H₂O₂ [94, 95] and on dopaminergic neurons from multiple insults in organotypic midbrain slice cultures. It potentiates cytochrome P450 2d22-mediated protection in paraquat- and maneb-induced PD by attenuating oxidative damage and DA depletion in 6-OHDA-induced rat model [96]. Resveratrol is able to protect the neurons in nigral cells [97]. Pinostilbene, one of the resveratrol derivatives, has also protective activity against 6-OHDA-induced neurotoxicity in SH-SY5Y cells [98].

20. *Psoralea corylifolia* L.

The aqueous extract of *Psoralea corylifolia* (Leguminosae) has inhibitory effect on dopamine and noradrenaline transporters [99]. The bakuchiol, isolated from *P. corylifolia*, inhibits monoamine transporters and regulates monoaminergic functions. It has dopaminergic protective activity as well as antiparkinsonian-like effects [100].

21. *Pueraria lobata* Willd and *Pueraria thomsonii* Benth

Pueraria lobata and *Pueraria thomsonii* (Leguminosae), as well as their active component, puerarin, have protective effects against MPP+-induced apoptosis in SH-SY5Y cells and dopaminergic neurons against 6-OHDA neurotoxicity through upregulation of glial cell line-derived neurotrophic factor. They also are able to inhibit the apoptosis in rat model of PD and regulate the effects of ubiquitin proteasome system [101, 102].

22. *Rhodiola crenulata*

Dried root and rhizoma of *Rhodiola crenulata* (Crassulaceae) and salidroside, one of its active components, are neuroprotective against MPP+-induced apoptosis in PC12 cells by activating PI3K/Akt and inhibiting the NO pathways [103].

23. *Salvia miltiorrhiza* Bge

The dried root and rhizoma of *Salvia miltiorrhiza* (Labiatae) and salvianolic acid A, salvianic acid A, and salvianolic acid B, derived from this plant, have protective effects against MPP+-induced neurotoxicity. Salvianolic acid A, through increasing the stress tolerance, is able to protect neurons against H₂O₂-induced injury. Salvianolic acid B is able to protect PC12 cells against H₂O₂-induced cytotoxicity and SH-SY5Y cells against MPP- or 6-OHDA-induced apoptosis [104-106].

24. *Scutellaria baicalensis* Georgi

Scutellaria baicalensis Georgi (Labiatae) and baicalein, one of its flavonoids, have neuroprotective activities in 6-OHDA induced PD. They also have protective effects against rotenone-induced neurotoxicity in isolated rat brain mitochondria and PC12 cells and protective effects against endoplasmic reticulum stress-induced apoptosis on HT22 murine hippocampal neuronal cells through substantial decrease in ROS production [107-109]. Baicalein possesses a neuroprotective effects against MPTP-induced neurotoxicity in mice model of PD and reduces the inflammation-mediated degeneration of dopaminergic neurons by inhibition of microglial activation [110, 111].

25. *Tripterygium wilfordii* Hook

The extract of *Tripterygium wilfordii* (Celastraceae) protects the dopaminergic neurons from LPS-induced inflammatory damage

[112]. Tripchlorolide and Triptolide, isolated from this plant, show neurotrophic and neuroprotective activities on dopaminergic neurons against LPS or MPP+-induced damage through immunosuppressive therapy or inhibition of microglial activation. They also upregulate nerve growth factor synthesis in rat astrocyte cultures and enhance the adeno-virus-mediated gene transfer in mice striatum [113, 114].

26. *Vicia faba* beans

Vicia faba beans, also known as faba bean, fava bean, broad bean, horse bean, field bean, tic bean or bell bean is a member of Fabaceae (pea) family. Fava beans contain levodopa and are able to control the symptoms of PD, the same as drugs containing levodopa. Fava beans are thought to contain substances other than levodopa and are helpful for PD symptoms. The effect of fava bean lasts longer than that of levodopa medications [115].

The amount of levodopa in the bean is enough to be pharmacologically active in PD. There are some reports indicating that the patients with PD would benefit from *Vicia faba* beans and in some cases the response to the beans might be better than conventional levodopa medications. At single dose the patients with PD having pronounced "on-off" motor oscillations benefited the effects of fava beans. The bean meal causes a longer response, which can be explained by higher plasma concentration. If both legumes and pods are ingested, the beans are relatively rich in protein. The beans could have potential advantages in reducing the off period [116].

Further research is needed to determine the efficacy of fava beans. In western countries, the fava beans are less known; therefore, their properties have been less understood, especially with regard to the levodopa content. It should be noted that various species of fava plants have different amounts of levodopa and the patients cannot be sure to obtain the exact amount. High levels of levodopa can cause nausea and raw fava beans can cause an allergic reaction in some patients [110].

Another consideration is the use of monoamine oxidase inhibitor drugs, including phenelzine, tranylcypromine and isocarboxazide taken with pressor compounds (foods high in tyramine, dopamine and phenylethylamine) which can cause a dangerous increase in blood pressure. The levodopa in fava or in medications can be converted to dopamine in the bloodstream. Favism which is an inherited disease in which the patients lack the enzyme glucose-6-phosphate dehydrogenase (G6PD) should also be considered in patients who eat fava beans. These patients may develop hemolytic anemia. G6PD deficiency is seen mostly among African, Southeast Asian and Mediterranean populations [117].

DISCUSSION AND CONCLUSION

The pathogenesis of PD has not been yet fully understood. There are growing bodies of evidence indicating that oxidative stress and inflammation have important role in PD pathogenesis. This knowledge has enabled us to link the mitochondrial dysfunction and oxidative stress with the pathogenesis of PD. *Substantia nigra* is vulnerable to oxidative damage. The main feature of PD is the loss of dopaminergic neurons in the *substantia nigra* [26].

Levodopa is the most effective medication for PD. It is converted into dopamine and then is metabolized to dopamine quinone which acts as the major source of oxidative stress. It has been shown that dopamine causes selective toxicity to dopaminergic terminals proportional to the levels of dopamine oxidation and quinone-modified proteins Dopamine quinone modifies some proteins such as DJ-1, UCH-L1 and α -synuclein which their dysfunctions have been shown to be linked to dopamine pathophysiology. Moreover, dopamine quinone-modified α -synuclein is able to inhibit normal degradation of other proteins [118]. Furthermore, dopamine quinone species are able to modify the cellular molecules such as protein cysteinyl residues and GSH whose normal functions

are crucial for cell survival [119]. These changes and other events induced by dopamine quinone suggest that plant antioxidants may have protective effect against dopamine toxicity on dopaminergic neurons.

The preventive and treatment strategies that counteract oxidative stress are encouraging in laboratory and animal models of PD. There are also studies suggesting agents that modulating mitochondrial function might be beneficial with regards to PD progression. However, the promising results of neuroprotective compounds in animal models have not been adequately tested in human clinical trials. It should be noted that oxidative stress and mitochondrial dysfunction are not specific to PD pathogenesis. There are a wide variety of other diseases such as cancer [120, 121], diabetes [122, 123], atherosclerosis [124, 125], infections [126, 127] and toxic conditions [128, 129] which are complicated by oxidative stress and treated with antioxidants. Hence, modulation of oxidative stress can help to manage other oxidative stress-related conditions, as well.

Another remarkable point is that PD in humans starts long before its clinical symptoms manifestation. Therefore, preventive measures should be taken to reduce the risk of disease. Hence, the use of antioxidant compounds can be crucial. Antioxidants are a variety of compounds which can scavenge free radicals [130, 131]. However, not all antioxidants have been effective on management of PD and other oxidative stress-induced diseases [132, 133]. In comparison to herbal antioxidants, single antioxidants including vitamins C and E seem to be less effective on rescuing the cells from apoptosis [134]. Further studies are needed to understand the mechanisms underlying the different protective capacities of herbal antioxidants and single antioxidants such as vitamins C and E.

Furthermore, the plants presented in this paper, alongside antioxidant activity, mostly have other compounds effective on PD. Hence, to what extent antioxidants are effective in prevention and treatment of PD should be investigated in clinical trials. If herbal antioxidants are effective per se, most plants with antioxidant activity [135-138] must contribute to treating PD, as well.

CONFLICT OF INTEREST

The authors confirm that this article content has no conflict of interest.

ACKNOWLEDGEMENTS

The authors gratefully thank Research and Technology Deputy of Shahrekord University of Medical Sciences for supporting this study.

CONTRIBUTIONS

AS, MB, HSh and MRK contributed to the collection of the data and preparation of first draft. AS and MRK edited the last version. All read and confirmed the last version.

REFERENCES

- [1] Bagetta V, Sgobio C, Pendolino V, *et al.* Rebalance of striatal NMDA/AMPA receptor ratio underlies the reduced emergence of dyskinesia during D2-like dopamine agonist treatment in experimental Parkinson's disease. *J Neurosci* 2012; 32: 17921-31.
- [2] Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. *Am Fam Physician* 2013; 87: 267-73.
- [3] Rao SS, Hofmann LA, Shakil A. Parkinson's disease: diagnosis and treatment. *Am Fam Physician* 2006; 74: 2046-54.
- [4] Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. *J Neuroimmune Pharmacol* 2013; 8: 189-201.
- [5] Jafari S, Etmnan M, Aminzadeh F, Samii A. Head injury and risk of Parkinson disease: A systematic review and meta-analysis. *Mov Disord* 2013; 28: 1222-9.
- [6] Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. *J Neuroimmune Pharmacol* 2013; 8: 189-201.

- [7] Li F, Zhu S, Wu C, Yan C, Liu Y, Shugan L. Neuroinflammation and cell therapy for Parkinson's disease. *Front Biosci* 2011; 3: 1407-20.
- [8] Yan MH, Wang X, Zhu X. Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. *Free Radic Biol Med* 2013; 62: 90-101.
- [9] Rabiei Z, Rafeian-Kopaei M. Neuroprotective effect of pretreatment with *Lavandula officinalis* ethanolic extract on blood-brain barrier permeability in a rat stroke model. *Asian Pacif J Trop Med* 2014; 7: S421-S6.
- [10] Lindvall O. Developing dopaminergic cell therapy for Parkinson's disease-give up or move forward? *Mov Disord* 2013; 28: 268-73.
- [11] Scovassi IA. Parkinson's disease: New insights. *Biochem & Pharmacol* 2013; 2: 3.
- [12] Jayaraj RL. An Overview of Parkinson's Disease and Oxidative Stress: Herbal Scenario. *Neuropathol Dis* 2012; 1(2): 95-122.
- [13] Blandini F. Neural and immune mechanisms in the pathogenesis of Parkinson's disease. *J Neuroimmune Pharmacol* 2013; 8: 189-201.
- [14] Beal MF. Mitochondria and neurodegeneration. *Novartis Found Symp* 2007; 287: 183-92.
- [15] Greenamyre JT, Hastings TG. Biomedicine. Parkinson's-divergent causes, convergent mechanisms. *Science* 2004; 304: 20-1122.
- [16] Hwang O. Role of Oxidative Stress in Parkinson's disease. *Exp Neurobiol* 2013; 22(1): 11-7.
- [17] Rafeian-Kopaei M, Nasri H. Re: Erythropoietin ameliorates oxidative stress and tissue injury following renal ischemia/reperfusion in rat kidney and lung. *Med Princ Pract* 2014; 23(1): 95.
- [18] Baradaran A, Nasri H, Rafeian-Kopaei M. Comment on: Anti-oxidative stress activity of *Stachys lavandulifolia* aqueous extract in humans. *Cell J* 2013; 15(3): 272-3.
- [19] Baradaran A, Nasri H, Rafeian-Kopaei M. Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. *J Res Med Sci* 2014; 19(4): 358-67.
- [20] Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science* 2004; 305: 626-9.
- [21] Weisskopf MG, O'reilly E, Chen H. Plasma urate and risk of Parkinson's disease. *Am J Epidemiol* 2007; 166: 561-7.
- [22] Van Laar VS, Mishizen AJ, Cascio M, *et al.* Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. *Neurobiol Dis* 2009; 34: 487-500.
- [23] Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. *Science* 2001; 294: 1346-9.
- [24] Qu W, Fan L, Kim YC, Kaempferol derivatives prevent oxidative stress-induced cell death in a DJ-1-dependent manner. *J Pharmacol Sci* 2009; 110: 191-200.
- [25] Zafar KS, Inayat-Hussain SH, Ross D. A comparative study of proteasomal inhibition and apoptosis induced in N27 mesencephalic cells by dopamine and MG132. *J Neurochem* 2007; 102: 913-21.
- [26] Zecca L, Wilms H, Geick S, *et al.* Human neuromelanin induces neuro-inflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease. *Acta Neuropathol* 2008; 116: 47-55.
- [27] Rabinovic AD, Lewis DA, Hastings TG. Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine. *Neuroscience* 2000; 101: 67-76.
- [28] Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. *J Bioenerg Biomembr* 2004; 36: 381-6.
- [29] Shults CW. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. *Arch Neurol* 2002; 59: 1541-50.
- [30] Lu KT. Neuroprotective effects of resveratrol on MPTP-induced neuron loss mediated by free radical scavenging. *J Agric Food Chem* 2008; 56: 6910-3.
- [31] Shirzad H, Taji F, Rafeian-Kopaei M. Correlation between antioxidant activity of garlic extracts and WEHI-164 fibrosarcoma tumor growth in BALB/c mice. *J Med Food* 2011; 14(9): 969-74.
- [32] Shirzad H, Shahrani M, Rafeian-Kopaei M. Comparison of morphine and tramadol effects on phagocytic activity of mice peritoneal phagocytes *in vivo*. *Int Immunopharmacol* 2009; 9(7-8): 968-70.

- [33] Bahmani M, Zargaran A, Rafeiean-Kopaei M, Saki M. Ethnobotanical study of medicinal plants used in the management of diabetes mellitus in the Urmia, Northwest Iran. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 348-54.
- [34] Mirhoseini M, Baradaran A, Rafeiean-Kopaei M. Medicinal plants, diabetes mellitus and urgent needs. *J Herbmec Pharmacol* 2013; 2(2): 53-4.
- [35] Rafeiean-Kopaei M, Shahinfard N, Rouhi-Boroujeni H, *et al.* Effects of *Ferulago angulata* extract on serum lipids and lipid peroxidation. *Evid-Base Compl Alternat Med* 2014 (2014), Article ID 680856, 4 pages <http://dx.doi.org/10.1155/2014/680856>.
- [36] Mirhosseini M, Baradaran A, Rafeiean-Kopaei M. Anethum graveolens and hyperlipidemia: A randomized clinical trial. *J Res Med Sci* 2014; 19: 758-61.
- [37] Bahmani M, Zargaran A, Rafeiean-Kopaei M. Identification of medicinal plants of Urmia for treatment of gastrointestinal disorders. *Rev Bras Farmacogn* 2014; 24: 468-48.
- [38] Bahmani M, Rafeiean-Kopaei M, Hassanzadazar H, Saki K, Karamati SA, Delfan B. A review on most important herbal and synthetic antihelmintic drugs. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 29-33.
- [39] Saki K, Bahmani M, Rafeiean-Kopaei M. The effect of most important medicinal plants on two important psychiatric disorders (anxiety and depression)-a review. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 34-42.
- [40] Bahmani M, Shirzad HA, Majlesi M, Shahinfard N, Rafeiean-Kopaei M. A review study on analgesic applications of Iranian medicinal plants. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 43-53.
- [41] Henchcliffe C, Flint-Beal M. Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. *Nature Neurol* 2009. doi: 10.1038/ncpneuro0924.
- [42] Rabiei Z, Rafeiean-kopaei M, Heidarian E, Saghaei E, Mokhtari S. Effects of zizyphus jujube extract on memory and learning impairment induced by bilateral electric lesions of the nucleus basalis of meynert in rat. *Neurochem Res* 2014; 39(2): 353-60.
- [43] Delfan B, Bahmani M, Hassanzadazar H, Saki K, Rafeiean-Kopaei M. Identification of medicinal plants affecting on headaches and migraines in Lorestan Province, West of Iran. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 376-9.
- [44] Asadi-Samani M, Bahmani M, Rafeiean-Kopaei M. The chemical composition, botanical characteristic and biological activities of *Borago officinalis*: a review. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 22-8.
- [45] Liu SM, Li XZ, Huo Y, Lu F. Protective effect of extract of *Acanthopanax senticosus* Harms on dopaminergic neurons in Parkinson's disease mice. *Phytomedicine* 2012; 19: 631-8.
- [46] Lahaie-Collins V, Bournival J, Plouffe M, Carange J, Martinoli MG. Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP⁺-induced oxidative stress. *Oxid Med Cell Longev* 2008; 1: 54-62.
- [47] Asgari S, Setorki M, Rafeiean-kopaei M, *et al.* Postprandial hypolipidemic and hypoglycemic effects of *Allium hertifolium* and *Sesamum indicum* on hypercholesterolemic rabbits. *Afr J Pharm Pharmacol* 2012; 6(15): 1131 -5.
- [48] Zhang ZJ, Cheang LC, Wang MW, *et al.* Ethanol extract of *fructus Alpinia oxyphylla* protects against 6-hydroxydopamine-induced damage of PC12 cells *in vitro* and dopaminergic neurons in zebrafish. *Cell Mol Neurobiol* 2012; 32: 27-40.
- [49] An LJ, Guan S, Shi GF, Bao YM, Duan YL, Jiang B. Protocatechuic acid from *Alpinia oxyphylla* against MPP⁺-induced neurotoxicity in PC12 cells. *Food Chem Toxicol* 2006; 44: 436-43.
- [50] Zhang ZG, Wu L, Wang JL, *et al.* Astragaloside IV prevents MPP⁺-induced SH-SY5Y cell death via the inhibition of Bax-mediated pathways and ROS production. *Mol Cell Biochem* 2012; 364: 209-16.
- [51] LI WX, Sun SG, Yuan H, Wang HT, Zhang YB, Sun BL. Time dependency of astragalus polysaccharides against systemic injury of free radical in astrocyte culture medium. *Chin J Clin Rehabil* 2006; 10: 56-61.
- [52] Tanaka K, Miyake Y, Fukushima W, *et al.* Intake of Japanese and Chinese teas reduces risk of Parkinson's disease. *Parkinsonism Relat Disord* 2011; 17: 446-50.
- [53] Guo S, Yan J, Yang T, Yang X, Bezard E, Zhao B. Protective effects of green tea polyphenols in the 6-OHDA rat model of Parkinson's disease through inhibition of ROS-NO pathway. *Biol Psychiatry* 2007; 62: 1353-62.
- [54] Li R, Peng N, Li XP, Le WD. (-)-Epigallocatechin gallate regulates dopamine transporter internalization via protein kinase C-dependent pathway. *Brain Res* 2006; 1097: 85-9.
- [55] Choi JY, Park CS, Kim DJ, *et al.* Prevention of nitric oxide-mediated 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced Parkinson's disease in mice by tea phenolic epigallocatechin 3-gallate. *Neurotoxicology* 2002; 23: 367-74.
- [56] Kim JS, Kim JM, O JJ, Jeon BS. Inhibition of inducible nitric oxide synthase expression and cell death by (-)-epigallocatechin-3-gallate, a green tea catechin, in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. *J Clin Neurosci* 2010; 17: 1165-8.
- [57] Asadi SY, Parsaei P, Karimi M, *et al.* Effect of green tea (*Camellia sinensis*) extract on healing process of surgical wounds in rat. *Int J Surg* 2013; 11(4): 332-7.
- [58] Asadi Y, Karimi M, Parsaei P, *et al.* Effects of *Camellia sinensis* Ethanolic Extract on Histometric and Histopathological Healing Process of Burn Wound in Rat. *Middle-East J Sci Res* 2013; 13 (1): 14-9.
- [59] Ju MS, Kim HG, Choi JG, *et al.* Cassiae semen, a seed of *Cassia obtusifolia*, has neuroprotective effects in Parkinson's disease models. *Food Chem Toxicol* 2010; 48: 2037-44.
- [60] Shin BY, Kim DH, Hyun SK, *et al.* Alaternin attenuates delayed neuronal cell death induced by transient cerebral hypoperfusion in mice. *Food Chem Toxicol* 2010; 48: 1528-36.
- [61] Kim IS, Koppula S, Park PJ, *et al.* *Chrysanthemum morifolium* Ramat (CM) extract protects human neuroblastoma SH-SY5Y cells against MPP⁺-induced cytotoxicity. *J Ethnopharmacol* 2009; 126: 447-54.
- [62] Kim IS, Ko HM, Koppula S, Kim BW, Choi DK. Protective effect of *Chrysanthemum indicum* Linne against 1-methyl-4-phenylpyridinium ion and lipopolysaccharide-induced cytotoxicity in cellular model of Parkinson's disease. *Food Chem Toxicol* 2011; 49: 963-73.
- [63] Li WW, Yang R, Cai DF. Protective effects of *Cistanche* total glycosides on dopaminergic neuron in substantia nigra of model mice of Parkinson's disease. *Zhongguo Zhong Xi Yi Jie He Za Zhi* 2008; 28: 248-51.
- [64] Zhao Q, Gao J, Li W, Cai D. Neurotrophic and neurorescue effects of echinacoside in the subacute MPTP mouse model of Parkinson's disease. *Brain Res* 2010; 1346: 224-36.
- [65] Gao Y, Pu XP. Neuroprotective effect of acteoside against rotenone-induced damage of SH-SY5Y cells and its possible mechanism. *Chin Pharmacol Bull* 2007; 23: 161-5.
- [66] Li ZG, Jiang B, Bao YM, An LJ. Protection of Semen *Cuscuta* extracts from apoptosis PC12 cell of induced by 1-methyl-4-phenylpyridinium. *Chin Tradit Pat Med* 2006; 28: 219-21.
- [67] Langley D. Exploiting the fungi: novel leads to new medicines. *Mycologist* 1998; 11: 165-6.
- [68] Komarova EL, Tolkachev ON. The chemistry of peptide ergot alkaloids. *Pharmaceut Chem J* 2001; 35: 504-6.
- [69] Robinson SL, Panaccione DG. Heterologous expression of lysergic acid and novel ergot alkaloids in *aspergillus fumigatus*. *Appl. Environ. Microbiol.* October 2014; 80(20): 6465-72.
- [70] Molina-Jimenez MF, Sanchez-Reus MI, Andres D, Cascales M, Benedi J. Neuroprotective effect of fraxetin and myricetin against rotenone-induced apoptosis in neuroblastoma cells. *Brain Res* 2004; 1009: 9-16.
- [71] Zhao DL, Zou LB, Lin S, Shi JG, Zhu HB. Anti-apoptotic effect of esculin on dopamine-induced cytotoxicity in the human neuroblastoma SH-SY5Y cell line. *Neuropharmacology* 2007; 53: 724-32.
- [72] Zhao DL, Shi L, Zhai KG, *et al.* Esculin, an extract from *Fraxinus sielboldiana* blume, protects SH-SY5Y cells from MPP⁺-induced cytotoxicity. *Acad J PLA Postgrad Med Sch* 2008; 29: 112-4.
- [73] An H, Kim IS, Koppula S, *et al.* Protective effects of *Gastrodia elata* Blume on MPP⁺-induced cytotoxicity in human dopaminergic SH-SY5Y cells. *J Ethnopharmacol* 2010; 130: 290-8.
- [74] Kim IS, Choi DK, Jung HJ. Neuroprotective effects of vanillyl alcohol in *Gastrodia elata* Blume through suppression of oxidative stress and anti-apoptotic activity in toxin-induced dopaminergic MN9D cells. *Molecules* 2011; 16: 5349-61.
- [75] In-Ho B, Seung-Ho SO. The world ginseng market and the ginseng. *J Ginseng Res.* 2013; 37(1): 1-6.

- [76] Mahady GB, Gyllenhall C, Fong HH, Farnsworth NR. Ginsengs: a review of safety and efficacy. *Nutr Clin Care* 2000; 3: 90-101.
- [77] Kaneko H. Proof of the mysterious efficacy of ginseng: basic and clinical trials: clinical effects of medical ginseng, Korean red ginseng: specifically, its anti-stress action for prevention of disease. *J Pharmacol Sci* 2004; 95(2): 158-62.
- [78] Wang P, Niu L, Guo XD, *et al.* Gypenosides protects dopaminergic neurons in primary culture against MPP(+)-induced oxidative injury. *Brain Res Bull* 2010; 83: 266-71.
- [79] Wang P, Niu L, Gao L, *et al.* Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson's disease. *J Int Med Res* 2010; 38: 1084-92.
- [80] Mohanasundari M, Sabesan M. Modulating effect of Hypericum perforatum extract on astrocytes in MPTP induced Parkinson's disease in mice. *Eur Rev Med Pharmacol Sci* 2007; 11: 17-20.
- [81] Lu YH, Du CB, Liu JW, Hong W, Wei DZ. Neuroprotective effects of Hypericum perforatum on trauma induced by hydrogen peroxide in PC12 cells. *Am J Chin Med* 2004; 32: 397-405.
- [82] Zou YP, Lu YH, Wei DZ. Protective effects of a flavonoid-rich extract of Hypericum perforatum L. against hydrogen peroxide induced apoptosis in PC12 cells. *Phytother Res* 2010; 24(Suppl 1): S6-S10.
- [83] Wang DQ, Wang W, Jing FC, Zhao JN. Effects of tetramethylpyrazine on the extracellular DA, its metabolites and hydroxyl radical in striatum of PD rats treated by L-DOPA. *Chin Pharm J* 2007; 42: 28-32.
- [84] Du J, Shan LC, Zhang GX, Wang YQ. Effect of TMP on dopaminergic neuron injury induced by MPTP *in vivo* and *in vitro*. *Lishizhen Med Mater Med Res* 2011; 22: 1564-5.
- [85] Verma DM, Balakrishnan NP, Dixit RD. Flora of Madhya Pradesh. Botanical Survey of India. Lucknow, India. 1993.
- [86] Pruriens M. Research Update. *Mucuna pruriens* in Parkinson's disease: a double blind clinical and pharmacological study. *J Neurol Neurosurg Psychiatry* 2004; 75(12): 1672-7.
- [87] Manyam BV, Dhanasekaran M, Hare TA. Effect of antiparkinson drug HP-200 (*Mucuna pruriens*) on the central monoaminergic neurotransmitters. *Phytother Res* 2004; 18(2): 97-101.
- [88] Liu DZ, Zhu J, Jin DZ, *et al.* Behavioral recovery following subchronic paeoniflorin administration in the striatal 6-OHDA lesion rodent model of Parkinson's disease. *J Ethnopharmacol* 2007; 112: 327-32.
- [89] Cao BY, Yang YP, Luo WF, *et al.* Paeoniflorin, a potent natural compound, protects PC12 cells from MPP+ and acidic damage via autophagic pathway. *J Ethnopharmacol* 2010; 131: 122-9.
- [90] Liu HQ, Zhang WY, Luo XT, Ye Y, Zhu XZ. Paeoniflorin attenuates neuroinflammation and dopaminergic neurodegeneration in the MPTP model of Parkinson's disease by activation of adenosine A1 receptor. *Br J Pharmacol* 2006; 148: 314-25.
- [91] Choi JG, Kim HG, Kim MC, *et al.* Polygalae radix inhibits toxin-induced neuronal death in the Parkinson's disease models. *J Ethnopharmacol* 2011; 134: 414-21.
- [92] Liang Z, Shi F, Wang Y, Lu L, Zhang Z, Wang X. Neuroprotective effects of tenuigenin in a SH-SY5Y cell model with 6-OHDA-induced injury. *Neurosci Lett* 2011; 497: 104-9.
- [93] Yuan HL, Li B, Xu J, *et al.* Tenuigenin protects dopaminergic neurons from inflammation-mediated damage induced by the lipopolysaccharide. *CNS Neurosci Ther* 2012; 18: 584-90.
- [94] Jeong JK, Moon MH, Bae BC, *et al.* Autophagy induced by resveratrol prevents human prion protein-mediated neurotoxicity. *Neurosci Res* 2012; 73: 99-105.
- [95] Bournival J, Quessy P, Martinoli MG. Protective effects of resveratrol and quercetin against MPP+ induced oxidative stress act by modulating markers of apoptotic death in dopaminergic neurons. *Cell Mol Neurobiol* 2009; 29: 1169-80.
- [96] Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced Parkinsonism in the mouse. *Free Radic Biol Med* 2012; 52: 1294-306.
- [97] Jin F, Wu Q, Lu YF, Gong QH, Shi JS. Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats. *Eur J Pharmacol* 2008; 600: 78-82.
- [98] Chao J, Li H, Cheng KW, Yu MS, Chang RC, Wang M. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. *J Nutr Biochem* 2010; 21: 482-9.
- [99] hao G, Li S, Qin GW, Fei J, Guo LH. Inhibitive effects of Fructus Psoraleae extract on dopamine transporter and noradrenaline transporter. *J Ethnopharmacol* 2007; 112: 498-506.
- [100] Zhao G, Zang SY, Zheng XW, Zhang XH, Guo LH. Bakuchiol analogs inhibit monoamine transporters and regulate monoaminergic functions. *Biochem Pharmacol* 2008; 75: 1835-47.
- [101] Zhu G, Wang X, Wu S, Li Q. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+ induced human neuroblastoma SH-SY5Y cell death. *Neurochem Int* 2012; 60: 400-8.
- [102] Zhu G, Wang X, Chen Y, *et al.* Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson's disease. *Planta Med* 2010; 76: 1820-6.
- [103] Li X, Ye X, Sun X, *et al.* Salidroside protects against MPP(+)-induced apoptosis in PC12 cells by inhibiting the NO pathway. *Brain Res* 2011; 1382: 9-18.
- [104] Wang XJ, Xu JX. Salvianic acid A protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity. *Neurosci Res* 2005; 51: 129-38.
- [105] Zhang HA, Gao M, Zhang L, *et al.* Salvianolic acid A protects human SH-SY5Y neuroblastoma cells against H2O2 induced injury by increasing stress tolerance ability. *Biochem Biophys Res Commun* 2012; 421: 479-83.
- [106] Tian LL, Wang XJ, Sun YN, *et al.* Salvianolic acid B, an antioxidant from *Salvia miltiorrhiza*, prevents 6hydroxydopamine induced apoptosis in SH-SY5Y cells. *Int J Biochem Cell Biol* 2008; 40: 409-22.
- [107] Mu X, He G, Cheng Y, Li X, Xu B, Du G. Baicalein exerts neuroprotective effects in 6 hydroxydopamine-induced experimental Parkinsonism *in vivo* and *in vitro*. *Pharmacol Biochem Behav* 2009; 92: 642-8.
- [108] Li XX, He GR, Mu X, *et al.* Protective effects of baicalein against rotenone-induced neurotoxicity in PC12 cells and isolated rat brain mitochondria. *Eur J Pharmacol* 2012; 674: 227-33.
- [109] Choi JH, Choi AY, Yoon H, *et al.* Baicalein protects HT22 murine hippocampal neuronal cells against endoplasmic reticulum stress-induced apoptosis through inhibition of reactive oxygen species production and CHOP induction. *Exp Mol Med* 2010; 42: 811-22.
- [110] Mu X, He GR, Yuan X, Li XX, Du GH. Baicalein protects the brain against neuron impairments induced by MPTP in C57BL/6 mice. *Pharmacol Biochem Behav* 2011; 98: 286-91.
- [111] Li FQ, Wang T, Pei Z, Liu B, Hong JS. Inhibition of microglial activation by the herbal flavonoid baicalein attenuates inflammation-mediated degeneration of dopaminergic neurons. *J Neural Transm* 2005; 112: 331-47.
- [112] Liu Y, Chen HL, Yang G. Extract of *Tripterygium wilfordii* Hook F protect dopaminergic neurons against lipopolysaccharide-induced inflammatory damage. *Am J Chin Med* 2010; 38: 801-14.
- [113] Li FQ, Cheng XX, Liang XB, *et al.* Neurotrophic and neuroprotective effects of triptchlorolide, an extract of Chinese herb *Tripterygium wilfordii* Hook F, on dopaminergic neurons. *Exp Neurol* 2003; 179: 28-37.
- [114] Xue B, Jiao J, Zhang L, *et al.* Triptolide upregulates NGF synthesis in rat astrocyte cultures. *Neurochem Res* 2007; 32: 1113-9.
- [115] Rabey JM, Vered Y, Shabtai H, Graff E, Harsat A, Korczyn AD. Broad bean (*Vicia faba*) consumption and Parkinson's disease. *Adv Neurol* 1993; 60: 681-4.
- [116] Baginsky C, Peña-Neira A, Cáceres A. *et al.* Phenolic compound composition in immature seeds of fava bean (*Vicia faba* L.) varieties cultivated in Chile. *J Food Compos Anal* 2013; 31(1): 1-6.
- [117] Essa MM, Braidy N, Bridge W. *et al.* Review of natural products on parkinson's disease pathology. *The J Aging Res Clin Pract* 2014; 3(1): 1-8.
- [118] Martinez-Vicente M, Tallozy Z, Kaushik S, *et al.* Dopamine- modified alpha-synuclein blocks chaperone-mediated autophagy. *J Clin Invest* 2008; 118: 777-88.
- [119] Conway KA, Rochet JC, Bieganski RM, Lansbury PT. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. *Science* 2001; 294: 1346-9.
- [120] Ghasemi-Pirbaluti M, Pourghesari B, Shirzad H, *et al.* Effect of Epigallocatechin-3-gallate (EGCG) on cell proliferation inhibition and apoptosis induction in lymphoblastic leukemia cell line. *J Hermed Pharmacol* 2015; 4(2): 65-8.

- [121] Shirzad H, Kiani M, Shirzad M. Impacts of tomato extract on the mice fibrosarcoma cells. *J Hermed Pharmacol* 2013; 2(1): 13-6.
- [122] Behradmanesh S, Horestani MK, Baradaran A, Nasri H. Association of serum uric acid with proteinuria in type 2 diabetic patients. *J Res Med Sci* 2013; 18: 44-6.
- [123] Rafieian-Kopaei M, Nasri H. The Ameliorative effect of Zingiber officinale in diabetic nephropathy. *Iran Red Crescent Med J* 2014 May; 16(5): e11324.
- [124] Asgary S, Kelishadi R, Rafieian-Kopaei M, Najafi S, Najafi M, Sahebkar A. Investigation of the lipid-modifying and antiinflammatory effects of Cornus mas L. supplementation on dyslipidemic children and adolescents. *Pediatr Cardiol* 2013; 34(7): 1729-35.
- [125] Asgary S, Rafieian-Kopaei M, Shamsi F, Najafi S, Sahebkar A. Biochemical and histopathological study of the anti-hyperglycemic and anti-hyperlipidemic effects of cornelian cherry (Cornus mas L.) in alloxan-induced diabetic rats. *J Complement Integr Med* 2014; 11(2): 63-9.
- [126] Rahimian G, Sanei MH, Shirzad H, *et al.* Virulence factors of Helicobacter pylori vacA increase markedly gastric mucosal TGF- β 1 mRNA expression in gastritis patients. *Microb Pathog* 2014 Feb-Mar; 67-68: 1-7. doi: 10.1016/j.micpath.2013.12.006. Epub 2014 Jan 21.
- [127] Bahmani M, Rafieian-Kopaei M, Hassanzadazar H, Saki K, Karamati SA, Delfan B. A review on most important herbal and synthetic antihelminthic drugs. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 29-33.
- [128] Taghikhani A, Afrough H, Ansari-Samani R, Shahinfard N, Rafieian-Kopaei M. Assessing the toxic effects of hydroalcoholic extract of Stachys lavandulifolia Vahl on rat's liver. *Bratisl Lek Listy* 2014; 115(3): 121-4.
- [129] Heidarian E, Rafieian-Kopaei M. Protective effect of artichoke (Cynara scolymus) leaf extract against lead toxicity in rat. *Pharm Biol* 2013; 51(9): 1104-9.
- [130] Nasri H, Rafieian-Kopaei M. Protective effects of herbal antioxidants on diabetic kidney disease. *J Res Med Sci* 2014; 19(1): 82-3.
- [131] Baradaran A, Nasri H, Nematbakhsh M, Rafieian-Kopaei M. Antioxidant activity and preventive effect of aqueous leaf extract of Aloe Vera on gentamicin-induced nephrotoxicity in male Wistar rats. *Clin Ter* 2014; 165(1): 7-11.
- [132] Nasri H, Rafieian-Kopaei M. Medicinal plants and antioxidants: Why they are not always beneficial? *Iranian Journal of Public Health* 2014; 43(2): 255-7.
- [133] Rafieian-Kopaei M, Baradaran A, Rafieian M. Oxidative stress and the paradoxical effects of antioxidants. *J Res Med Sci* 2013; 18(7): 628.
- [134] Offen D, Ziv I, Sternin H, Melamed E, Hochman A. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. *Experimental Neurology* 1996; 141(1): 32-9.
- [135] Asadbeigi M, Mohammadi T, Rafieian-Kopaei M, Saki K, Bahmani M, Delfan B. Traditional effects of medicinal plants in the treatment of respiratory diseases and disorders: an ethnobotanical study in the Urmia. *Asian Pac J Trop Med* 2014; 7(Suppl 1): S364-8.
- [136] Parsaei P, Karimi M, Asadi SY, Rafieian-Kopaei M. Bioactive components and preventive effect of green tea (Camellia sinensis) extract on postlaparotomy intra-abdominal adhesion in rats. *Int J Surg* 2013; <http://dx.doi.org/10.1016/j.ijssu.2013.08.014>.
- [137] Delfan B, Bahmani M, Rafieian-Kopaei M, Delfan M, Saki K. A review study on ethnobotanical study of medicinal plants used in relief of toothache in Lorestan Province, Iran. *Asian Pac J Trop Dis* 2014; 4(Suppl 2): 879-84.
- [138] Bahmani M, Saki K, Rafieian-Kopaei M, Karamati SA, Eftekhari Z, Jelodari M. The most common herbal medicines affecting Sarcostigmaphora branches: a review study. *Asian Pac J Trop Med* 2014; 7(Suppl 1): 14-21